Whistleblower Success for Claudine Q. Homolash
The Pharmaceutical company Astellas Pharma US, Inc. has agreed to pay the United States a total of $7.3 million to resolve allegations that it violated the False Claims Act by illegally marketing and promoting the drug Mycamine® for pediatric use and to pediatric institutions.
The settlement resolves allegations brought in a whistleblower action filed in the Eastern District of Pennsylvania in March 2010 under the False Claims Act, which permits private citizens to bring lawsuits alleging violations of the Act...
View full press release